The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
- Published In:
- Diabetes, obesity & metabolism, 23 Suppl 3, 5-29 (2021)
- Authors:
- Nauck, Michael A(8), Quast, Daniel R(3), Wefers, Jakob(2), Pfeiffer, Andreas F H
- Database ID:
- RPEP-05642
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05642APA
Nauck, Michael A; Quast, Daniel R; Wefers, Jakob; Pfeiffer, Andreas F H. (2021). The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.. Diabetes, obesity & metabolism, 23 Suppl 3, 5-29. https://doi.org/10.1111/dom.14496
MLA
Nauck, Michael A, et al. "The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.." Diabetes, 2021. https://doi.org/10.1111/dom.14496
RethinkPeptides
RethinkPeptides Research Database. "The evolving story of incretins (GIP and GLP-1) in metabolic..." RPEP-05642. Retrieved from https://rethinkpeptides.com/research/nauck-2021-the-evolving-story-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.